VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates
VAXART (VXRT) delivered earnings and revenue surprises of +22.22% and +1,206.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -13.68% and -5.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
The Beauty Health Company (SKIN) Surpasses Q2 Earnings and Revenue Estimates
Beauty Health (SKIN) delivered earnings and revenue surprises of +150.00% and +4.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
Select Medical (SEM) Surpasses Q2 Earnings and Revenue Estimates
Select Medical (SEM) delivered earnings and revenue surprises of +14.29% and +1.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching
Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.
Stocktwits·11mo ago
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside...
Yahoo! Finance: News·1y ago
Vaxart Stock Is Moving Higher After The Bell: What's Going On?
Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds from a recent offering combined with reimbursements under its Project...
Benzinga·1y ago
FDA Changes Course, Advises Updated COVID-19 Vaccines Target KP.2 Strain
FDA Changes Course, Advises Updated COVID-19 Vaccines Target KP.2 Strain
Authored by Zachary Stieber via The Epoch Times (emphasis ours),
A healthcare worker prepares a COVID-19 vaccine...